Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
Status:
Terminated
Trial end date:
2020-05-07
Target enrollment:
Participant gender:
Summary
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
patients with connective tissue disease-associated pulmonary arterial hypertension to
determine the recommended dose range and evaluate the change from baseline in 6-minute walk
distance (6MWD) following 24 weeks of study participation.